Float Short %

4.92

Margin Of Safety %

Put/Call OI Ratio

0.07

EPS Next Q Diff

0.2

EPS Last/This Y

0.7

EPS This/Next Y

0.58

Price

0.3

Target Price

5.5

Analyst Recom

Performance Q

-29.28

Relative Volume

0.32

Beta

-0.16

Ticker: LPTX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	LPTX	0.2679	0.13	0.00	4239
2025-08-18	LPTX	0.2874	0.08	0.00	5290
2025-08-19	LPTX	0.2827	0.08	0.00	5305
2025-08-20	LPTX	0.2651	0.08	0.02	5305
2025-08-21	LPTX	0.2725	0.08	0.00	5213
2025-08-22	LPTX	0.2927	0.08	0.00	5264
2025-08-25	LPTX	0.3055	0.08	0.00	5333
2025-08-26	LPTX	0.2914	0.08	0.09	5491
2025-08-27	LPTX	0.2952	0.08	0.00	5703
2025-08-28	LPTX	0.295	0.08	0.00	5708
2025-08-29	LPTX	0.2901	0.08	0.00	5719
2025-09-02	LPTX	0.2905	0.07	0.00	5743
2025-09-03	LPTX	0.2902	0.07	0.00	5744
2025-09-04	LPTX	0.2858	0.07	0.00	5844
2025-09-05	LPTX	0.278	0.07	0.00	5859
2025-09-08	LPTX	0.2819	0.07	0.00	5861
2025-09-09	LPTX	0.2827	0.07	0.00	5860
2025-09-10	LPTX	0.2802	0.07	0.00	5859
2025-09-11	LPTX	0.2877	0.07	0.00	5867
2025-09-12	LPTX	0.2943	0.07	0.00	5868
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	LPTX	0.27	44.2	-	-1.11
2025-08-18	LPTX	0.28	44.2	-	-1.11
2025-08-19	LPTX	0.29	44.2	-	-1.11
2025-08-20	LPTX	0.27	44.2	-	-1.11
2025-08-21	LPTX	0.27	44.2	-	-1.11
2025-08-22	LPTX	0.30	45.5	-	-1.11
2025-08-25	LPTX	0.31	45.5	-	-1.11
2025-08-26	LPTX	0.30	45.5	-	-1.11
2025-08-28	LPTX	0.30	45.5	-	-1.11
2025-08-29	LPTX	0.29	45.5	-	-1.11
2025-09-02	LPTX	0.29	45.5	-	-1.11
2025-09-03	LPTX	0.28	45.5	-	-1.11
2025-09-04	LPTX	0.28	45.5	-	-1.11
2025-09-05	LPTX	0.28	45.5	-	-1.11
2025-09-08	LPTX	0.29	45.5	-	-1.11
2025-09-09	LPTX	0.28	45.5	-	-1.11
2025-09-10	LPTX	0.28	45.5	-	-1.11
2025-09-11	LPTX	0.29	45.5	-	-1.11
2025-09-12	LPTX	0.30	45.5	-	-1.11
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	LPTX	0.00	-21.31	4.97
2025-08-18	LPTX	0.00	-25.26	4.57
2025-08-19	LPTX	0.00	-25.26	4.57
2025-08-20	LPTX	0.00	-25.26	4.57
2025-08-21	LPTX	0.00	-25.26	4.57
2025-08-22	LPTX	0.00	-25.26	4.57
2025-08-25	LPTX	0.00	-24.18	4.57
2025-08-26	LPTX	0.00	-24.18	4.57
2025-08-27	LPTX	0.00	-24.18	5.19
2025-08-28	LPTX	0.00	-24.18	5.19
2025-08-29	LPTX	0.00	-24.18	5.19
2025-09-02	LPTX	0.00	-24.18	5.19
2025-09-03	LPTX	0.00	-24.18	5.19
2025-09-04	LPTX	0.00	-24.18	5.19
2025-09-05	LPTX	0.00	-24.18	5.19
2025-09-08	LPTX	0.00	-24.21	5.19
2025-09-09	LPTX	0.00	-24.21	5.19
2025-09-10	LPTX	0.00	-24.21	5.19
2025-09-11	LPTX	0.00	-24.21	4.92
2025-09-12	LPTX	0.00	-24.21	4.92
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.4

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.2

Insider Transactions

Institutional Transactions

-24.21

Beta

-0.16

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.3

Max Drawdown 5-Year %

-99.4

Target Price

5.5

P/E

Forward P/E

PEG

P/S

P/B

2.16

P/Free Cash Flow

EPS

-1.59

Average EPS Est. Cur. Y

-1.11

EPS Next Y. (Est.)

-0.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.32

Return on Equity vs Sector %

-1173.8

Return on Equity vs Industry %

-1160.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.15

EBIT Estimation

Leap Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 52

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

stock quote shares LPTX – Leap Therapeutics Inc Stock Price stock today

news today LPTX – Leap Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch LPTX – Leap Therapeutics Inc yahoo finance google finance

stock history LPTX – Leap Therapeutics Inc invest stock market

stock prices LPTX premarket after hours

ticker LPTX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: LPTX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y